Iradimed (IRMD) Net Margin (2013 - 2026)

Iradimed (IRMD) has 14 years of Net Margin data on file, last reported at 26.47% in Q1 2026.

• Net Margin for Q1 2026 came in at 26.47%, up 245.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 27.36% (up 104.0% YoY), and the FY2025 annual result was 26.82%, up 56.0% from the prior year.
• Net Margin slipped to 26.47% in Q1 2026 per IRMD's latest filing, from 28.39% in the prior quarter.
• Over five years, Net Margin peaked at 30.7% in Q3 2023 and troughed at 17.86% in Q4 2023.
• A 5-year average of 25.34% and a median of 25.91% in 2023 frame the typical range for Net Margin.
• On a YoY basis, Net Margin climbed as much as 1050 bps in 2022 and fell as far as 807 bps in 2022.
• A 5-year view of Net Margin shows it stood at 24.72% in 2022, then dropped by 28 bps to 17.86% in 2023, then surged by 49 bps to 26.54% in 2024, then increased by 7 bps to 28.39% in 2025, then decreased by 7 bps to 26.47% in 2026.
• Business Quant data shows IRMD's Net Margin at 26.47% in Q1 2026, 28.39% in Q4 2025, and 26.3% in Q3 2025.